Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at HC Wainwright

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $42.00 target price on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 381.65% from the stock’s previous close.

Separately, D. Boral Capital restated a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research note on Wednesday, February 12th.

Anavex Life Sciences Stock Down 8.6 %

NASDAQ:AVXL opened at $8.72 on Monday. The stock has a market capitalization of $741.76 million, a price-to-earnings ratio of -15.85 and a beta of 0.94. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $14.44. The firm has a 50 day moving average of $9.01 and a 200 day moving average of $8.32.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. As a group, analysts expect that Anavex Life Sciences will post -0.69 EPS for the current year.

Institutional Trading of Anavex Life Sciences

Several large investors have recently added to or reduced their stakes in AVXL. Wellington Management Group LLP purchased a new stake in Anavex Life Sciences in the fourth quarter valued at approximately $1,704,000. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Anavex Life Sciences by 69.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 26,673 shares of the biotechnology company’s stock valued at $286,000 after acquiring an additional 10,925 shares during the last quarter. PVG Asset Management Corp increased its stake in shares of Anavex Life Sciences by 503.5% in the fourth quarter. PVG Asset Management Corp now owns 78,490 shares of the biotechnology company’s stock worth $843,000 after acquiring an additional 65,485 shares during the period. Vermillion Wealth Management Inc. purchased a new position in shares of Anavex Life Sciences during the fourth quarter worth $34,000. Finally, Squarepoint Ops LLC lifted its position in Anavex Life Sciences by 304.9% during the fourth quarter. Squarepoint Ops LLC now owns 67,627 shares of the biotechnology company’s stock valued at $726,000 after purchasing an additional 50,924 shares during the period. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.